News
CRITICARE, February 15-19, Pune, India
January 24 2012
Conference on Continuous Renal Replacement Therapies (CRRT), February 12-15, San Diego, USA
January 24 2012
MEDLAB, Arab Health, January 23-26, Dubai, UAE
January 16 2012
An addition to the Obesity and Type 2 Diabetes antibody portfolio
December 22 2011
Better kidney markers ahead?
December 05 2011
New NGAL.com website launched
November 24 2011
MEDICA, November 16-19, Düsseldorf, Germany
October 26 2011
ASN Kidney Week, November 8-13, Pennsylvania, Philadelphia, USA
October 20 2011
ESICM 2011, October 1-5, Berlin, Germany
September 06 2011
AACC Clinical Lab Expo, July 24-28, Atlanta
July 04 2011
Expansion of the peptide hormone antibody portfolio
August 23 2010 by BioPorto Diagnostics
BioPorto Diagnostics is pleased to announce the launch of new monoclonal antibodies
The launch of two new anti-ghrelin antibodies provides a tool for measuring total ghrelin levels in human sample. The two antibodies are designed to work together as a sandwich antibody pair to give sensitive measurements.
BioPorto Diagnostics offers an extensive range of monoclonal antibodies within the peptide hormone area. These antibodies are widely used by researchers and pharmaceutical companies around the world. Especially in the field of obesity and type-2 diabetes, these antibodies give researchers a unique opportunity to measure relevant peptide hormones.
